Call us Toll Free at 1-866-242-0905 or
Click here to begin your FREE Case Review
Trasylol, also known as Aprotinin, is an injectable drug which intends to prevent excessive blood loss in patients recovering from cardiac bypass surgery and coronary artery bypass grafts. These conditions require prolonged recovery time to properly heal, and even small bleeding wounds can become immediately catastrophic without any indication or external symptom. Tragically, the injection has been linked to severe consequences ranging from heart attacks to chronic kidney failure.
Recently, many patients have experienced post-operative complications that can be attributed to the drug, and the resulting firestorm of controversy has led to thousands of legal claims filed against Bayer Pharmaceuticals, the producer and manufacturer of Trasylol.
Alarming statistics regarding the impacts of Trasylol recently published in the New England Journal of Medicine have led the FDA to an issue an advisory regarding a safety evaluation that is currently being conducted to assess the drug’s risks. Additionally, the FDA has advised doctors to carefully weigh the risks and benefits of Trasylol before administering the drug to patients.
Then on September 29, 2006, Bayer alerted the FDA to the results they conducted on the potential dangers of Trasylol. This study discovered that Trasylol use could cause severe and potentially life-threatening complications such as stroke, heart attack, congestive heart failure, and kidney failure. This study reinforced two previous studies that linked Trasylol to adverse side effects, and hastened the FDA’s decision to advise doctors to its potential dangers.
Anyone who has been treated with Trasylol should discuss their situation with experienced and compassionate lawyer who will help determine what action can and should be taken against those who failed to inform you of the very real risks associated with Trasylol use.
